activity ratio by a factor of 2.0 \ m=+-\ 0.2 in the intact uterus. Salbutamol, the positive control, increased this activity ratio in both longitudinal myometrium (by 1.9 \ m=+-\ 0.3 times) and in the intact uterus (by 3.8 \ m=+-\ 0.3 times), whereas the negative control levcromakalim had no effect. Relaxin seems to act as a relaxant of longitudinal myometrium by a cyclic
Introduction
Relaxin, a polypeptide hormone, is a potent relaxant of utérine smooth muscle (Downing and Hollingsworth, 1993) . However, the signal-transduction pathway underlying this effect is uncer¬ tain (Hughes and Hollingsworth, 1995, 1996) . One hypothesis is that relaxin interacts with plasmalemma receptors in myometrial cells and activates adenylyl cyclase, resulting in the increased formation of cAMP and activation of cAMPdependent protein kinase A (PKA) (Sanborn et al, 1980 (Sanborn et al, , 1994 .
Evidence supporting the existence of this pathway is the fact that relaxin increases cAMP concentrations in the uterus in vitro (Cheah and Sherwood, 1980; Judson et al, 1980; Sanborn et al, 1980; Hsu et al, 1985; Osa et al, 1991) and after treatment in vivo (Downing et al, 1992) . In addition, relaxin increases the total activity of protein kinase A (PKA) in the rat uterus (Kemp and Niall, 1981) (H-8) (Hidaka et al, 1984; Hagiwara et al, 1987) in rat myometrial cells in culture (Anwer et al, 1990 ). H-8 also antagonizes relaxin as a uterine relaxant (Sanborn et al, 1994 al, 1980; Hsu et al., 1985) . Second, the time courses for the increase in uterine cAMP concentrations in vitro (Sanborn et al, 1980; Hsu et al, 1985) and for PKA activation (Kemp and Niall, 1981) (Downing et al, 1992) . Finally, low concentrations of relaxin have a pharmacological profile consistent with a primary site of action at the plasmalemma in the modification of ion channel activity (Hughes and Hollingsworth, 1995 (Corbin, 1983) . Small changes in cAMP are often associated with larger changes in PKA activity (Corbin, 1983) , a feature known as amplification (Kenakin, 1993) , and so PKA activity may be a preferable biochemical index. PKA is present in the rat uterus, both in the endometrium and myometrium (Korenman and Krall, 1977) . cAMP-PKA consists of two regulatory and two catalytic subunits (Corbin, 1983 (Corbin, 1983) .
Another explanation for some of the inconsistencies listed above may be that relaxin acts partly or totally indirectly via the release of a factor from the endometrium. Although some of the biochemical studies have been conducted with myometrial cells (Anwer et al, 1990; Sanborn et al, 1994) (l-NAME), an inhibitor of nitric oxide synthase (Norman, 1996) (Diamond, 1990) ; and nifedipine, a Ca -channel blocker (Granger et al, 1986 (Glass et al, 1989 (Hughes and Hollingsworth, 1995) . Cumulative addition of levcromakalim (0.025-0.8 µ l"1), salbutamol (0.125-8 µ l"1) or relaxin (0.8-50 nmol 1~) produced a reversible, concentration-dependent reduction of the integral of oxytocin-induced tension waves (Fig. 1 ).
H-8 (100 µ l"1) shifted the log10 concentration-effect curves for salbutamol and relaxin to the right by factors of 1.9 and 3.1, respectively ( Fig. 1; Table 1 ). In the presence of H-8 (Fig. 3) . The lowest concentration of salbutamol tested (30 nmol 1~1 ) did not modify the PKA activity ratio in either tissue preparation. The PKA activity ratio was raised following incubation with the higher concentrations of salbutamol (300 nmol 1~~1 , 3000 nmol 1 ) in both the intact uterus and longitudinal myometrium (Fig. 3a,b) . In the presence of the highest concentration of salbutamol (3000 nmol 1~: ), the PKA activity ratio in the intact uterus was 3.8 ± 0.3 times the basal activity ratio, whereas the PKA activity ratio in the longitudinal myometrium was 1.9 ± 0.3 times the basal activity ratio.
Relaxin. The basal PKA activity ratio was again slightly but significantly higher (P < 0.05) in tissue extracts from longitudinal myometrium than in extracts from intact uterus (0.16 ±0.03 and 0.11 ±0.02, respectively) (Fig. 4) . Relaxin did not increase the PKA activity ratio in the longitudinal myometrium (Fig. 4a) . However, in the intact uterus, relaxin induced a small and significant (P < 0.05) rise in the PKA activity ratio at concentrations of 300 nmol 1_1 (1.8 ±0.2 times the basal activity ratio) and 3000 nmol 1~( 2.0 ± 0.2 times the basal activity ratio; Fig. 4b ). The time course of the effect of relaxin (300 nmol 1~1 ) upon PKA activity in the intact uterus is shown (Fig. 5) . The PKA activity ratio was maximally raised (to 1.8 + 0.2 times the control value) 1 min after the tissue had been exposed to relaxin, and remained raised for 6 min. (Edwards and Weston, 1994 (Corbin, 1983; Murray et al, 1990) . The inhibitor PKI(6-22)amide (1 µ 1~' ) almost completely inhibited drug-induced activity, demonstrating activation and specific measurement of PKA.
It is well known that salbutamol activates the adenylyl cyclase pathway (Diamond, 1990) (Hsu et al, 1985) , or changes were measured in intact uterus (Judson et al, 1980; Grazi et al, 1988) .
Given the absence of any PKA stimulation in the longitudi¬ nal myometrium with relaxin, the stimulation of PKA seen in the intact uterus must be localized to the circular muscle layer or the endometrium. Unfortunately, it is technically extremely difficult to separate the circular myometrium from the endometrium. The observation that oxytocin-induced spasm was maximally inhibited by relaxin by only 60% in the longitudinal myometrium but that complete inhibition of this spasm was induced by relaxin in the intact uterus indicates that a part of the inhibitory action of relaxin in the intact uterus is effected via the circular muscle layer or the endometrium. It is possible that relaxin stimulates a cAMP-PKA-dependent pro¬ cess in the circular myometrium/endometrium that results in the release of a factor that acts in turn upon the longitudinal myometrium and leads to relaxation. It might have been speculated that the inhibitory factor is nitric oxide, which has been shown to be a relaxant of the uterus in the pregnant rat (Yallampalli et al, 1993) . However, relaxin was not antagonized by L-NAME, the nitric oxide synthase inhibitor, discounting NO as the intermediary.
In summary, the relaxant action of relaxin in the longi¬ tudinal myometrium is independent of cAMP-dependent protein kinase and presumably does not involve the adenylyl cyclase pathway. In contrast, relaxin has an action involving the adenylyl cyclase pathway in the circular myometrium and/or the endometrium and perhaps the release of a relaxant factor.
